Shire Resolves Litigation Related to Vyvanse, Adderall XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:20PM CDT
Shire plc (SHPG) announced that it has reached a final agreement with the U.S. Attorney's Offices for the Eastern District of Pennsylvania and the Northern District of Illinois, all 50 states and the District of Columbia.
Pharma Stocks Review - AbbVie, Merck, Johnson and Johnson, GlaxoSmithKline, and Bristol-Myers Squibb
PR Newswire - Thu Sep 25, 8:20AM CDT
On Wednesday, September 24, 2014, the NASDAQ Composite ended at 4,555.22, up 1.03%, the Dow Jones Industrial Average advanced 0.90%, to finish the day at 17,210.06, and the S&P 500 closed at 1,998.30, up 0.78%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 755.42, up 1.68%, with the index also advancing 7.83% in the previous three months. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Merck and Company Inc. (NYSE: MRK), Johnson and Johnson (NYSE: JNJ), GlaxoSmithKline PLC (NYSE: GSK), and Bristol-Myers Squibb Company (NYSE: BMY). Free research on these five companies can be accessed at:
AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease
PR Newswire - Thu Sep 25, 7:00AM CDT
AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for HUMIRA in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home.
Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:00PM CDT
Gilead (GILD) is seeking Japanese approval for the combination of Sovaldi and ledipasvir .
Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.
Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.
Will New Treasury Rules Contain Tax Inversions? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Sep 24, 9:22AM CDT
Late on Monday, the U.S. Treasury Department outlined new rules to deter domestic companies from moving abroad in an attempt to reduce tax payments.
3 Top Dividend Growth Stocks to Buy in October
Motley Fool Staff - Motley Fool - Wed Sep 24, 9:15AM CDT
Income investors have always prized dividend stocks for their steady income potential, while growth investors seek market-beating share price growth to make up for lost dividends. But what about stocks providing both dividends and growth? For these...
Stock Market News for September 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 9:10AM CDT
Markets ended in the red zone for the third consecutive day as sluggish growth data from the Eurozone and air strikes in Syria offset China’s encouraging economic data
Celgene's
at Investor's Business Daily - Tue Sep 23, 5:45PM CDT
Celgene's (CELG) Otezla received FDA approval for the oral treatment of psoriasis, which causes red, scaly patches on the skin and affects 7.5 mil Americans. It's typically treated with injections, like AbbVie's (ABBV) Humira. Celgene shares rose 1%...
Stock Market Today: U.S. Stocks in 3-Day Losing Streak as U.S. Strikes Syria
at The Street - Tue Sep 23, 3:47PM CDT
The U.S. stocks fell for a third day as U.S. fighter jets attack the Islamic State militia in Syria.
Stocks Fall To Session Lows; Vipshop Bucks The Trend
at Investor's Business Daily - Tue Sep 23, 2:00PM CDT
Selling picked up the pace in the major averages in late-afternoon trading Tuesday. The Dow Jones industrial average fell 0.6%; the S&P 500 gave up 0.4% and the Nasdaq lost 0.3%. NYSE and Nasdaq volume was tracking about 5% to 10% lower than Monday's...
U.S. Treasury Cracks Down on Tax Inversions - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Sep 23, 1:15PM CDT
Tax inversions could be a thing of the past thanks to new rules from the U.S. Treasury Department.
Stocks Lower In Afternoon Trading; CarMax Plunges
at Investor's Business Daily - Tue Sep 23, 12:23PM CDT
The market was lower in afternoon trading Tuesday in what is proving to be an erratic session. The Nasdaq was down 0.1%, the S&P 500 0.3% and the Dow Jones industrial average 0.4%. Volume was tracking lower across the board. The stock market today...
Shares Feel The Squeeze Of Treasury's Inversion Rules
at Investor's Business Daily - Tue Sep 23, 11:25AM CDT
The Treasury Department's new rules cracking down on tax inversions -- U.S. companies' moving their headquarters overseas to take advantage of lower corporate tax rates -- had an immediate impact on investors as they traded down businesses so...
Why Jim Cramer Would Buy AbbVie (ABBV), St. Jude Medical (STJ) Stock on Tax Inversion News
at The Street - Tue Sep 23, 10:51AM CDT
TheStreet's Jim Cramer explains why he would buy AbbVie (ABBV) and St. Jude Medical (STJ) stock in the wake of the Treasury Department's tax inversion plan.
Why AbbVie (ABBV) Stock Is Down Today
at The Street - Tue Sep 23, 9:01AM CDT
Shares of AbbVie (ABBV) fell in morning trading Tuesday after the U.S. Treasury Department and the IRS announced a plan to decrease inversion tax benefits.
Global Tensions and Fear - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Sep 23, 8:51AM CDT
The start of an expanded air campaign in the Iraq-Syria theater and weak data out of Europe provide the unsettling backdrop for today's trading action.
Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical